Mabwell (Shanghai) Bioscience Co., Ltd.
Equities
688062
CNE100005RD2
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
33.6 CNY | +1.33% | -3.97% | +2.78% |
May. 07 | Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821 | CI |
Apr. 29 | Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.78% | 1.86B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- 688062 Stock
- News Mabwell (Shanghai) Bioscience Co., Ltd.
- Mabwell Scraps Licensing Deal With Yangtze River Pharma